Evan Ya-Wen Yu
M.D., University of Washington, 1998.
B.S., University of Washington, Zoology, 1994.
Dr. Evan Yu is an Assistant Professor of Medicine at the University of Washington Department of Medicine and an associate member of the Fred Hutchinson Cancer Research Center. He received training in a clinical environment and also a basic science arena studying cancer biology at Harvard Medical School and the Dana-Farber Cancer Institute. This provided him with the foundation of scientific knowledge and experience to proceed as a physician-investigator, focusing on translational efforts to test novel therapeutics and discover unique cancer-related biomarkers. Dr. Yu is currently in collaboration with Dr. David Mankoff of Nuclear Medicine, evaluating PET scans in with novel radiotracers as a marker of treatment response for patients with metastatic prostate cancer. He is also studying the role of Fatty Acid Synthase as it relates to 11C-acetate PET uptake and prostate cancer biology. He has plans for multiple PET studies in the future that evaluate bone and even image the androgen receptor. He is testing multiple novel agents in prostate cancer that target multiple kinases, survivin, and clusterin (anti-apoptotic protein). His overall goal is to discover novel biomarkers with predictive clinical value that can help guide treatment and aid in the development of novel therapeutics for patients with prostate cancer.
(Reading, Writing, Speaking)
Chinese, Mandarin: (Functional, Functional, Fluent)
American Association for Cancer Research
American Medical Association
American Society of Clinical Oncology
American Society of Internal Medicine
American Urological Association
Massachusetts Medical Society
Southwest Oncology Group
2002-2004, Post-doctoral Basic Science Research Fellow, Dana-Farber Cancer Institute
2001-2004, Clinical Fellow in Medicine, Dana-Farber Cancer Institute
2001-2004, Fellow in Hematology-Oncology, Dana-Farber Cancer Institute
2000-2001, Senior Assistant Resident, Brigham and Women's Hospital
1999-2000, Junior Assistant Resident, Brigham and Women's Hospital
1998-1999, Intern in Medicine, Brigham and Women's Hospital
1998-2004, Clinical Fellow in Medicine, Harvard University, Medical School
SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(14):1601-8.. 2015.
Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 56(3):354-60.. 2015.
Delayed antiandrogen withdrawal syndrome after discontinuation of bicalutamide.. Clinical genitourinary cancer. 13(1):e51-3.. 2015.
Role of Maximal Endoscopic Resection Before Cystectomy for Invasive Urothelial Bladder Cancer.. Clinical genitourinary cancer.. 2014.
The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions.. Asian journal of andrology.. 2014.
Nonresponse to Neoadjuvant Chemotherapy for Muscle-Invasive Urothelial Cell Carcinoma of the Bladder.. Clinical genitourinary cancer.. 2013.
Castrate-resistant prostate cancer: postdocetaxel management.. Current opinion in urology.. 2013.
A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.. Cancer chemotherapy and pharmacology.. 2013.
Abiraterone in metastatic prostate cancer without previous chemotherapy.. The New England journal of medicine. 368(2):138-48.. 2013.
Prostate cancer: Bone density testing--essential or extraneous? Nature reviews. Urology. 10(1):11-2.. 2013.
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.. The lancet oncology. 14(13):1307-16.. 2013.
Advanced clinical States in prostate cancer.. The Urologic clinics of North America. 39(4):561-71.. 2012.
Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(15):1864-70.. 2012.
C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy.. Clinical nuclear medicine. 36(3):192-8.. 2011.